TGF-B receptor inhibitors are primarily used in research and therapeutic applications to study and modulate the TGF-beta signaling pathway, which plays a critical role in cell growth, differentiation, and immune regulation. In cancer research, these inhibitors are employed to block TGF-beta signaling, which is often hijacked by tumors to promote metastasis and immune evasion. By inhibiting this pathway, researchers aim to reduce tumor progression and enhance the effectiveness of anti-cancer therapies. Additionally, TGF-B receptor inhibitors are explored in fibrotic diseases, such as liver or lung fibrosis, where excessive TGF-beta signaling contributes to tissue scarring. Inhibiting this pathway can potentially slow or reverse fibrotic damage. In autoimmune diseases, these inhibitors are investigated for their ability to suppress overactive immune responses driven by TGF-beta signaling. Overall, TGF-B receptor inhibitors serve as valuable tools in both understanding disease mechanisms and developing targeted treatments.